Eva Fortea Verdejo
Stock Analyst at Wells Fargo
(0.03)
# 4,363
Out of 4,784 analysts
7
Total ratings
14.29%
Success rate
-28.05%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Eva Fortea Verdejo
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ITOS iTeos Therapeutics | Maintains: Overweight | $19 → $17 | $6.32 | +168.99% | 3 | Mar 6, 2025 | |
| XNCR Xencor | Maintains: Overweight | $37 → $33 | $11.23 | +193.86% | 2 | Feb 28, 2025 | |
| RCUS Arcus Biosciences | Initiates: Overweight | $29 | $8.17 | +254.96% | 1 | Oct 8, 2024 | |
| KNSA Kiniksa Pharmaceuticals International, | Initiates: Overweight | $34 | $23.09 | +47.25% | 1 | May 3, 2024 |
iTeos Therapeutics
Mar 6, 2025
Maintains: Overweight
Price Target: $19 → $17
Current: $6.32
Upside: +168.99%
Xencor
Feb 28, 2025
Maintains: Overweight
Price Target: $37 → $33
Current: $11.23
Upside: +193.86%
Arcus Biosciences
Oct 8, 2024
Initiates: Overweight
Price Target: $29
Current: $8.17
Upside: +254.96%
Kiniksa Pharmaceuticals International,
May 3, 2024
Initiates: Overweight
Price Target: $34
Current: $23.09
Upside: +47.25%